Affinity Asset Advisors, LLC has filed its 13F form on May 14, 2025 for Q1 2025 where it was disclosed a total value porftolio of $896 Million distributed in 98 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Xenon Pharmaceuticals Inc. with a value of $44.6M, Verona Pharma PLC with a value of $39M, Arcellx, Inc. with a value of $34.8M, Alkermes Plc. with a value of $33M, and Nuvalent, Inc. with a value of $32.6M.

Examining the 13F form we can see an increase of $336M in the current position value, from $560M to 896M.

Affinity Asset Advisors, LLC is based out at New York, NY

Below you can find more details about Affinity Asset Advisors, LLC portfolio as well as his latest detailed transactions.

Portfolio value $896 Million
Healthcare: $555 Million
ETFs: $341 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 98
  • Current Value $896 Million
  • Prior Value $560 Million
  • Filing
  • Period Q1 2025
  • Filing Date May 14, 2025
  • Form Type 13F-HR
  • Activity in Q1 2025
  • New Purchases 20 stocks
  • Additional Purchases 28 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 17 stocks
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.